Ensuring Best Access to CF Treatment
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study tests whether people with cystic fibrosis who are already on a triple combination CFTR modulator can stay on their treatment without interruptions or problems. It aims to make sure everyone gets the best, most consistent treatment for their CF.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with cystic fibrosis (CF) and have a known type of CF gene change.
- You are 2 years old or older.
- You have been taking a stable dose of a triple combination CFTR modulator (like Trikafta) for at least 2 weeks before the study starts.
- Your lung disease has been stable—no big drop in lung function or need for extra antibiotics in the past 4 weeks.
- You can understand and agree to the study procedures, either yourself or with a parent/guardian.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether doing airway clearance therapies less often can be just as effective as doing them every day for children and teens with cystic fibrosis who are taking a modulator medicine. The goal is to see if a simpler treatment schedule can keep lungs healthy while making daily life easier.
This study looks at how the medicine elexacaftor/tezacaftor/ivacaftor (often called Trikafta) works in the body in people with cystic fibrosis. It helps doctors understand the right dose and how the drug is processed, which may improve treatment for children and adults.
This study looks at how the drug Trikafta (also called Kaftrio) works in children aged 2 to 17 with cystic fibrosis. The goal is to learn how the body processes the medicine so doctors can find the best dose.
This study looks at how the triple combination therapy (elexacaftor/tezacaftor/ivacaftor, or ETI) affects your body's metabolism, epigenetics, and gut bacteria in people with cystic fibrosis. It aims to understand the broader health benefits of this treatment.
This study measures how antibiotics are processed by the body in people with cystic fibrosis who are taking a combination drug called elexacaftor/tezacaftor/ivacaftor (ETI). Understanding this helps doctors prescribe the right antibiotic doses for patients on this newer treatment.
This study tests whether a special nutrition supplement can improve health in adults with cystic fibrosis and pancreatic insufficiency who are already on a modulator therapy. The goal is to see if the supplement helps with digestion and overall well-being.
Hear when a new Cystic Fibrosis (CF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.